Atossa Therapeutics (NASDAQ:ATOS) Earns “Buy” Rating from HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 322.54% from the stock’s previous close.

ATOS has been the topic of a number of other research reports. Ascendiant Capital Markets increased their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th. StockNews.com raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, October 25th.

Atossa Therapeutics Trading Up 2.9 %

Shares of NASDAQ:ATOS opened at $1.42 on Thursday. Atossa Therapeutics has a 1-year low of $0.62 and a 1-year high of $2.31. The stock has a market capitalization of $178.58 million, a P/E ratio of -6.76 and a beta of 1.20. The business has a 50-day moving average price of $1.43 and a two-hundred day moving average price of $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities analysts predict that Atossa Therapeutics will post -0.22 EPS for the current year.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares during the period. XTX Topco Ltd bought a new position in shares of Atossa Therapeutics during the 2nd quarter valued at about $29,000. Renaissance Technologies LLC grew its position in shares of Atossa Therapeutics by 11.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after purchasing an additional 164,540 shares during the period. Rhumbline Advisers bought a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $161,000. Finally, Bank of New York Mellon Corp raised its holdings in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the period. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.